Equities

Iteos Therapeutics Inc

ITOS:NMQ

Iteos Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)8.30
  • Today's Change0.17 / 2.09%
  • Shares traded179.97k
  • 1 Year change-14.43%
  • Beta1.3689
Data delayed at least 15 minutes, as of Nov 22 2024 19:58 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments532613849
Total Receivables, Net6.502.4412
Total Inventory------
Prepaid expenses121314
Other current assets, total------
Total current assets551628875
Property, plant & equipment, net116.777.40
Goodwill, net------
Intangibles, net------
Long term investments101118--
Note receivable - long term4.511.132.00
Other long term assets0.880.330.30
Total assets668755885
LIABILITIES
Accounts payable117.665.15
Accrued expenses172118
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total1214281
Total current liabilities4042304
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total525028
Total liabilities9292332
SHAREHOLDERS EQUITY
Common stock0.040.040.04
Additional paid-in capital464436413
Retained earnings (accumulated deficit)125237141
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(13)(9.64)(1.02)
Total equity575663553
Total liabilities & shareholders' equity668755885
Total common shares outstanding363635
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.